Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational Therapeutics
- Rare disease company in preclinical development for congenital hyperinsulinism - - Acquisition is strong strategic fit...
COVID-19
Agile Therapeutics Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement
PRINCETON, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile” or the “Company”), a women's healthcare...
180 Life Sciences Announces Presentation at the Gordon Conference
PALO ALTO, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the...
BioAtla Announces Change in Executive Leadership
SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the...
Windtree Announces Istaroxime Scientific Abstract Has Been Accepted at the 2023 Technology and Heart Failure Therapeutics Conference
WARRINGTON, Pa., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company...
Gain Therapeutics Presents New Preclinical Data from its Gaucher Disease Program at the 19th Annual WORLDSymposium
Study results support the disease-modifying potential of GCase-targeting small molecule therapy for neuronopathic Gaucher diseaseBETHESDA, Md., Feb. 27, 2023 (GLOBE...
PDS Biotech Completes Successful Meeting with FDA for Triple Combination of PDS0101, PDS0301 and a Commercial Immune Checkpoint Inhibitor
Received guidance on registrational path for combination in recurrent/metastatic, immune checkpoint inhibitor refractory head and neck cancerFLORHAM PARK, N.J., Feb....
UpHealth Announces Strategic Sale of Innovations Group Incorporated to Belmar Pharma Solutions for Approximately $56 Million in Gross Proceeds
~ Represents a Substantial Milestone in UpHealth’s Focus on Further Integration of its Telehealth, Integrated Care and Behavioral Health Businesses...
Lucira Health Announces FDA Authorization of First & Only At-Home Combination Covid-19 & Flu Test and Comments on Chapter 11 Bankruptcy Filing
Test Delivers Lab-Quality Performance with Results in 30 Minutes or Less – The First At-Home Test to Ever Include Flu...
Lyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer
Lyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer Lyra Therapeutics CTO John Bishop, Ph.D. WATERTOWN, Mass.,...
Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at AAAAI 2023
- Rapid, profound and durable responses across multiple dosing groups with favorable safety profile observed—positioning barzolimab as a potential best-in-class...
SELLAS Life Sciences Announces Pricing of $20.0 Million Underwritten Public Offering
NEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a...
SeaStar Medical’s Selective Cytopheretic Device to be Featured at the 5th Chronic Kidney Disease Drug Development Summit
DENVER, Feb. 24, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical...
Windtree Therapeutics Announces Issuance of New Istaroxime Patent from U.S. Patent and Trademark Office
New Patent Adds to the Istaroxime Patent Estate and Provides Intellectual Property Protection Until Late 2039WARRINGTON, Pa., Feb. 24, 2023...
Chembio Announces the Receipt of CLIA Waiver for its DPP HIV-Syphilis System
MEDFORD, N.Y., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious...
Libtayo® (cemiplimab) in Combination with Chemotherapy Receives Positive CHMP Opinion for the Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
Recommendation based on a Phase 3 trial demonstrating superior survival outcomes for Libtayo plus chemotherapy compared to chemotherapy aloneTARRYTOWN, N.Y.,...
Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330
WTX-330 is designed as systemically delivered, conditionally activated IL-12 therapy Phase 1 Study of WTX-330 is intended to evaluate the...
BioCryst Presents New Long-term and Real-world Data Demonstrating Sustained Reductions in Hereditary Angioedema Attack Rates and Improvement in Quality of Life with ORLADEYO® (berotralstat)
— Final safety and effectiveness analysis from APeX-S showed ORLADEYO 150 mg resulted in a median attack rate of 0.0...
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
NEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting data from the ULTIMATE I...
Pharvaris to Highlight Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks at AAAAI Annual Meeting
ZUG, Switzerland, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to...